Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 30 entries
Sorted by: Best Match Show Resources per page
Toll-like receptor 9 in breast cancer.

Frontiers in immunology

Sandholm J, Selander KS.
PMID: 25101078
Front Immunol. 2014 Jul 22;5:330. doi: 10.3389/fimmu.2014.00330. eCollection 2014.

Toll-like receptor 9 (TLR9) is a cellular DNA receptor of the innate immune system. DNA recognition via TLR9 results in an inflammatory reaction, which eventually also activates a Th1-biased adaptive immune attack. In addition to cells of the immune...

Cite
Sandholm J, Selander KS. Toll-like receptor 9 in breast cancer. Front Immunol. 2014;5:330doi: 10.3389/fimmu.2014.00330.
Sandholm, J., & Selander, K. S. (2014). Toll-like receptor 9 in breast cancer. Frontiers in immunology, 5330. https://doi.org/10.3389/fimmu.2014.00330
Sandholm, Jouko, and Selander, Katri S. "Toll-like receptor 9 in breast cancer." Frontiers in immunology vol. 5 (2014): 330. doi: https://doi.org/10.3389/fimmu.2014.00330
Sandholm J, Selander KS. Toll-like receptor 9 in breast cancer. Front Immunol. 2014 Jul 22;5:330. doi: 10.3389/fimmu.2014.00330. eCollection 2014. PMID: 25101078; PMCID: PMC4105583.
Copy Download .nbib Format: NLM
Computer science. Solving imperfect-information games.

Science (New York, N.Y.)

Sandholm T.
PMID: 25574004
Science. 2015 Jan 09;347(6218):122-3. doi: 10.1126/science.aaa4614.

No abstract available.

Cite
Sandholm T. Computer science. Solving imperfect-information games. Science. 2015;347(6218):122-3doi: 10.1126/science.aaa4614.
Sandholm, T. (2015). Computer science. Solving imperfect-information games. Science (New York, N.Y.), 347(6218), 122-3. https://doi.org/10.1126/science.aaa4614
Sandholm, Tuomas. "Computer science. Solving imperfect-information games." Science (New York, N.Y.) vol. 347,6218 (2015): 122-3. doi: https://doi.org/10.1126/science.aaa4614
Sandholm T. Computer science. Solving imperfect-information games. Science. 2015 Jan 09;347(6218):122-3. doi: 10.1126/science.aaa4614. PMID: 25574004.
Copy Download .nbib Format: NLM
Atmospheric ammonia measurement using a VUV/photo-fragmentation laser-induced fluorescence technique.

Applied optics

Schendel JS, Stickel RE, Vandijk CA, Sandholm ST, Davis DD, Bradshaw JD.
PMID: 20577487
Appl Opt. 1990 Nov 20;29(33):4924-37. doi: 10.1364/AO.29.004924.

Vacuum ultraviolet/photofragmentation laser-induced fluorescence has been demonstrated to be a highly specific and sensitive method for the quantitative measurement of atmospheric ammonia (NH(3)). The fluorescence detected in this approach results from the two 193-nm photon photofragmentation step NH(3)?NH(2)? NH(b(1)Sigma(+))...

Cite
Schendel JS, Stickel RE, Vandijk CA, et al. Atmospheric ammonia measurement using a VUV/photo-fragmentation laser-induced fluorescence technique. Appl Opt. 1990;29(33):4924-37doi: 10.1364/AO.29.004924.
Schendel, J. S., Stickel, R. E., Vandijk, C. A., Sandholm, S. T., Davis, D. D., & Bradshaw, J. D. (1990). Atmospheric ammonia measurement using a VUV/photo-fragmentation laser-induced fluorescence technique. Applied optics, 29(33), 4924-37. https://doi.org/10.1364/AO.29.004924
Schendel, J S, et al. "Atmospheric ammonia measurement using a VUV/photo-fragmentation laser-induced fluorescence technique." Applied optics vol. 29,33 (1990): 4924-37. doi: https://doi.org/10.1364/AO.29.004924
Schendel JS, Stickel RE, Vandijk CA, Sandholm ST, Davis DD, Bradshaw JD. Atmospheric ammonia measurement using a VUV/photo-fragmentation laser-induced fluorescence technique. Appl Opt. 1990 Nov 20;29(33):4924-37. doi: 10.1364/AO.29.004924. PMID: 20577487.
Copy Download .nbib Format: NLM
Alendronate-induced disruption of actin cytoskeleton and inhibition of migration/invasion are associated with cofilin downregulation in PC-3 prostate cancer cells.

Oncotarget

Virtanen SS, Ishizu T, Sandholm JA, Löyttyniemi E, Väänänen HK, Tuomela JM, Härkönen PL.
PMID: 30220968
Oncotarget. 2018 Aug 24;9(66):32593-32608. doi: 10.18632/oncotarget.25961. eCollection 2018 Aug 24.

Bisphosphonates are used for prevention of osteoporosis and metastatic bone diseases. Anti-invasive effects on various cancer cells have also been reported, but the mechanisms involved are not well-understood. We investigated the effects of the nitrogen-containing bisphosphonate alendronate (ALN) on...

Cite
Virtanen SS, Ishizu T, Sandholm JA, et al. Alendronate-induced disruption of actin cytoskeleton and inhibition of migration/invasion are associated with cofilin downregulation in PC-3 prostate cancer cells. Oncotarget. 2018;9(66):32593-32608doi: 10.18632/oncotarget.25961.
Virtanen, S. S., Ishizu, T., Sandholm, J. A., Löyttyniemi, E., Väänänen, H. K., Tuomela, J. M., & Härkönen, P. L. (2018). Alendronate-induced disruption of actin cytoskeleton and inhibition of migration/invasion are associated with cofilin downregulation in PC-3 prostate cancer cells. Oncotarget, 9(66), 32593-32608. https://doi.org/10.18632/oncotarget.25961
Virtanen, Sanna S, et al. "Alendronate-induced disruption of actin cytoskeleton and inhibition of migration/invasion are associated with cofilin downregulation in PC-3 prostate cancer cells." Oncotarget vol. 9,66 (2018): 32593-32608. doi: https://doi.org/10.18632/oncotarget.25961
Virtanen SS, Ishizu T, Sandholm JA, Löyttyniemi E, Väänänen HK, Tuomela JM, Härkönen PL. Alendronate-induced disruption of actin cytoskeleton and inhibition of migration/invasion are associated with cofilin downregulation in PC-3 prostate cancer cells. Oncotarget. 2018 Aug 24;9(66):32593-32608. doi: 10.18632/oncotarget.25961. eCollection 2018 Aug 24. PMID: 30220968; PMCID: PMC6135693.
Copy Download .nbib Format: NLM
Combination treatment optimization using a pan-cancer pathway model.

PLoS computational biology

Schmucker R, Farina G, Faeder J, Fröhlich F, Saglam AS, Sandholm T.
PMID: 34962919
PLoS Comput Biol. 2021 Dec 28;17(12):e1009689. doi: 10.1371/journal.pcbi.1009689. eCollection 2021 Dec.

The design of efficient combination therapies is a difficult key challenge in the treatment of complex diseases such as cancers. The large heterogeneity of cancers and the large number of available drugs renders exhaustive in vivo or even in...

Cite
Schmucker R, Farina G, Faeder J, et al. Combination treatment optimization using a pan-cancer pathway model. PLoS Comput Biol. 2021;17(12):e1009689doi: 10.1371/journal.pcbi.1009689.
Schmucker, R., Farina, G., Faeder, J., Fröhlich, F., Saglam, A. S., & Sandholm, T. (2021). Combination treatment optimization using a pan-cancer pathway model. PLoS computational biology, 17(12), e1009689. https://doi.org/10.1371/journal.pcbi.1009689
Schmucker, Robin, et al. "Combination treatment optimization using a pan-cancer pathway model." PLoS computational biology vol. 17,12 (2021): e1009689. doi: https://doi.org/10.1371/journal.pcbi.1009689
Schmucker R, Farina G, Faeder J, Fröhlich F, Saglam AS, Sandholm T. Combination treatment optimization using a pan-cancer pathway model. PLoS Comput Biol. 2021 Dec 28;17(12):e1009689. doi: 10.1371/journal.pcbi.1009689. eCollection 2021 Dec. PMID: 34962919.
Copy Download .nbib Format: NLM
Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood.

Clinical kidney journal

Huang S, Sandholm K, Jonsson N, Nilsson A, Wieslander A, Grundström G, Hancock V, Ekdahl KN.
PMID: 25713707
Clin Kidney J. 2015 Feb;8(1):31-7. doi: 10.1093/ckj/sfu127. Epub 2014 Dec 01.

BACKGROUND: The use of acetate in haemodialysis fluids may induce negative effects in patients including nausea and increased inflammation. Therefore, haemodialysis fluids where acetate is substituted with citrate have recently been developed. In this study, we investigated the biocompatibility...

Cite
Huang S, Sandholm K, Jonsson N, et al. Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood. Clin Kidney J. 2014;8(1):31-7doi: 10.1093/ckj/sfu127.
Huang, S., Sandholm, K., Jonsson, N., Nilsson, A., Wieslander, A., Grundström, G., Hancock, V., & Ekdahl, K. N. (2015). Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood. Clinical kidney journal, 8(1), 31-7. https://doi.org/10.1093/ckj/sfu127
Huang, Shan, et al. "Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood." Clinical kidney journal vol. 8,1 (2015): 31-7. doi: https://doi.org/10.1093/ckj/sfu127
Huang S, Sandholm K, Jonsson N, Nilsson A, Wieslander A, Grundström G, Hancock V, Ekdahl KN. Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood. Clin Kidney J. 2015 Feb;8(1):31-7. doi: 10.1093/ckj/sfu127. Epub 2014 Dec 01. PMID: 25713707; PMCID: PMC4310429.
Copy Download .nbib Format: NLM
Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition.

Frontiers in oncology

Siddiqui A, Tumiati M, Joko A, Sandholm J, Roering P, Aakko S, Vainionpää R, Kaipio K, Huhtinen K, Kauppi L, Tuomela J, Hietanen S.
PMID: 34616682
Front Oncol. 2021 Sep 20;11:733700. doi: 10.3389/fonc.2021.733700. eCollection 2021.

Critical DNA repair pathways become deranged during cancer development. This vulnerability may be exploited with DNA-targeting chemotherapy. Topoisomerase II inhibitors induce double-strand breaks which, if not repaired, are detrimental to the cell. This repair process requires high-fidelity functional homologous...

Cite
Siddiqui A, Tumiati M, Joko A, et al. Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition. Front Oncol. 2021;11:733700doi: 10.3389/fonc.2021.733700.
Siddiqui, A., Tumiati, M., Joko, A., Sandholm, J., Roering, P., Aakko, S., Vainionpää, R., Kaipio, K., Huhtinen, K., Kauppi, L., Tuomela, J., & Hietanen, S. (2021). Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition. Frontiers in oncology, 11733700. https://doi.org/10.3389/fonc.2021.733700
Siddiqui, Arafat, et al. "Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition." Frontiers in oncology vol. 11 (2021): 733700. doi: https://doi.org/10.3389/fonc.2021.733700
Siddiqui A, Tumiati M, Joko A, Sandholm J, Roering P, Aakko S, Vainionpää R, Kaipio K, Huhtinen K, Kauppi L, Tuomela J, Hietanen S. Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition. Front Oncol. 2021 Sep 20;11:733700. doi: 10.3389/fonc.2021.733700. eCollection 2021. PMID: 34616682; PMCID: PMC8488401.
Copy Download .nbib Format: NLM
Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study.

Journal of the American Society of Nephrology : JASN

Parsa A, Kanetsky PA, Xiao R, Gupta J, Mitra N, Limou S, Xie D, Xu H, Anderson AH, Ojo A, Kusek JW, Lora CM, Hamm LL, He J, Sandholm N, Jeff J, Raj DE, Böger CA, Bottinger E, Salimi S, Parekh RS, Adler SG, Langefeld CD, Bowden DW, Groop PH, Forsblom C, Freedman BI, Lipkowitz M, Fox CS, Winkler CA, Feldman HI.
PMID: 27729571
J Am Soc Nephrol. 2017 Mar;28(3):923-934. doi: 10.1681/ASN.2015101152. Epub 2016 Oct 11.

The rate of decline of renal function varies significantly among individuals with CKD. To understand better the contribution of genetics to CKD progression, we performed a genome-wide association study among participants in the Chronic Renal Insufficiency Cohort Study. Our...

Cite
Parsa A, Kanetsky PA, Xiao R, et al. Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study. J Am Soc Nephrol. 2016;28(3):923-934doi: 10.1681/ASN.2015101152.
Parsa, A., Kanetsky, P. A., Xiao, R., Gupta, J., Mitra, N., Limou, S., Xie, D., Xu, H., Anderson, A. H., Ojo, A., Kusek, J. W., Lora, C. M., Hamm, L. L., He, J., Sandholm, N., Jeff, J., Raj, D. E., Böger, C. A., Bottinger, E., Salimi, S., Parekh, R. S., Adler, S. G., Langefeld, C. D., Bowden, D. W., Groop, P. H., Forsblom, C., Freedman, B. I., Lipkowitz, M., Fox, C. S., Winkler, C. A., Feldman, H. I. (2017). Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study. Journal of the American Society of Nephrology : JASN, 28(3), 923-934. https://doi.org/10.1681/ASN.2015101152
Parsa, Afshin, et al. "Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study." Journal of the American Society of Nephrology : JASN vol. 28,3 (2017): 923-934. doi: https://doi.org/10.1681/ASN.2015101152
Parsa A, Kanetsky PA, Xiao R, Gupta J, Mitra N, Limou S, Xie D, Xu H, Anderson AH, Ojo A, Kusek JW, Lora CM, Hamm LL, He J, Sandholm N, Jeff J, Raj DE, Böger CA, Bottinger E, Salimi S, Parekh RS, Adler SG, Langefeld CD, Bowden DW, Groop PH, Forsblom C, Freedman BI, Lipkowitz M, Fox CS, Winkler CA, Feldman HI. Genome-Wide Association of CKD Progression: The Chronic Renal Insufficiency Cohort Study. J Am Soc Nephrol. 2017 Mar;28(3):923-934. doi: 10.1681/ASN.2015101152. Epub 2016 Oct 11. PMID: 27729571; PMCID: PMC5328149.
Copy Download .nbib Format: NLM
Hypoxia regulates Toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro.

Oncology letters

Sandholm J, Tuomela J, Kauppila JH, Harris KW, Graves D, Selander KS.
PMID: 24959259
Oncol Lett. 2014 Jul;8(1):266-274. doi: 10.3892/ol.2014.2095. Epub 2014 Apr 25.

Toll-like receptor-9 (TLR9) is a cellular DNA sensor of the innate immune system. TLR9 is widely expressed in a number of tumors, including brain cancer; however, little is known regarding its regulation and involvement in cancer pathophysiology. The present...

Cite
Sandholm J, Tuomela J, Kauppila JH, et al. Hypoxia regulates Toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro. Oncol Lett. 2014;8(1):266-274doi: 10.3892/ol.2014.2095.
Sandholm, J., Tuomela, J., Kauppila, J. H., Harris, K. W., Graves, D., & Selander, K. S. (2014). Hypoxia regulates Toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro. Oncology letters, 8(1), 266-274. https://doi.org/10.3892/ol.2014.2095
Sandholm, Jouko, et al. "Hypoxia regulates Toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro." Oncology letters vol. 8,1 (2014): 266-274. doi: https://doi.org/10.3892/ol.2014.2095
Sandholm J, Tuomela J, Kauppila JH, Harris KW, Graves D, Selander KS. Hypoxia regulates Toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro. Oncol Lett. 2014 Jul;8(1):266-274. doi: 10.3892/ol.2014.2095. Epub 2014 Apr 25. PMID: 24959259; PMCID: PMC4063648.
Copy Download .nbib Format: NLM
Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes.

Journal of internal medicine

Jansson Sigfrids F, Dahlström EH, Forsblom C, Sandholm N, Harjutsalo V, Taskinen MR, Groop PH.
PMID: 33964025
J Intern Med. 2021 Sep;290(3):632-645. doi: 10.1111/joim.13298. Epub 2021 May 08.

BACKGROUND: We aimed to assess whether remnant cholesterol concentration and variability predict the progression of diabetic nephropathy (DN) and severe diabetic retinopathy (SDR) in type 1 diabetes.METHODS: This observational prospective study covered 5150 FinnDiane Study participants. Remnant cholesterol was...

Cite
Jansson Sigfrids F, Dahlström EH, Forsblom C, et al. Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes. J Intern Med. 2021;290(3):632-645doi: 10.1111/joim.13298.
Jansson Sigfrids, F., Dahlström, E. H., Forsblom, C., Sandholm, N., Harjutsalo, V., Taskinen, M. R., & Groop, P. H. (2021). Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes. Journal of internal medicine, 290(3), 632-645. https://doi.org/10.1111/joim.13298
Jansson Sigfrids, F, et al. "Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes." Journal of internal medicine vol. 290,3 (2021): 632-645. doi: https://doi.org/10.1111/joim.13298
Jansson Sigfrids F, Dahlström EH, Forsblom C, Sandholm N, Harjutsalo V, Taskinen MR, Groop PH. Remnant cholesterol predicts progression of diabetic nephropathy and retinopathy in type 1 diabetes. J Intern Med. 2021 Sep;290(3):632-645. doi: 10.1111/joim.13298. Epub 2021 May 08. PMID: 33964025.
Copy Download .nbib Format: NLM
Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (.

Journal of the American Society of Nephrology : JASN

Mychaleckyj JC, Valo E, Ichimura T, Ahluwalia TS, Dina C, Miller RG, Shabalin IG, Gyorgy B, Cao J, Onengut-Gumuscu S, Satake E, Smiles AM, Haukka JK, Tregouet DA, Costacou T, O'Neil K, Paterson AD, Forsblom C, Keenan HA, Pezzolesi MG, Pragnell M, Galecki A, Rich SS, Sandholm N, Klein R, Klein BE, Susztak K, Orchard TJ, Korstanje R, King GL, Hadjadj S, Rossing P, Bonventre JV, Groop PH, Warram JH, Krolewski AS.
PMID: 34261756
J Am Soc Nephrol. 2021 Oct;32(10):2634-2651. doi: 10.1681/ASN.2020101457. Epub 2021 Jul 14.

No abstract available.

Cite
Mychaleckyj JC, Valo E, Ichimura T, et al. Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (. J Am Soc Nephrol. 2021;32(10):2634-2651doi: 10.1681/ASN.2020101457.
Mychaleckyj, J. C., Valo, E., Ichimura, T., Ahluwalia, T. S., Dina, C., Miller, R. G., Shabalin, I. G., Gyorgy, B., Cao, J., Onengut-Gumuscu, S., Satake, E., Smiles, A. M., Haukka, J. K., Tregouet, D. A., Costacou, T., O'Neil, K., Paterson, A. D., Forsblom, C., Keenan, H. A., Pezzolesi, M. G., Pragnell, M., Galecki, A., Rich, S. S., Sandholm, N., Klein, R., Klein, B. E., Susztak, K., Orchard, T. J., Korstanje, R., King, G. L., Hadjadj, S., Rossing, P., Bonventre, J. V., Groop, P. H., Warram, J. H., & Krolewski, A. S. (2021). Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (. Journal of the American Society of Nephrology : JASN, 32(10), 2634-2651. https://doi.org/10.1681/ASN.2020101457
Mychaleckyj, Josyf C, et al. "Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (." Journal of the American Society of Nephrology : JASN vol. 32,10 (2021): 2634-2651. doi: https://doi.org/10.1681/ASN.2020101457
Mychaleckyj JC, Valo E, Ichimura T, Ahluwalia TS, Dina C, Miller RG, Shabalin IG, Gyorgy B, Cao J, Onengut-Gumuscu S, Satake E, Smiles AM, Haukka JK, Tregouet DA, Costacou T, O'Neil K, Paterson AD, Forsblom C, Keenan HA, Pezzolesi MG, Pragnell M, Galecki A, Rich SS, Sandholm N, Klein R, Klein BE, Susztak K, Orchard TJ, Korstanje R, King GL, Hadjadj S, Rossing P, Bonventre JV, Groop PH, Warram JH, Krolewski AS. Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (. J Am Soc Nephrol. 2021 Oct;32(10):2634-2651. doi: 10.1681/ASN.2020101457. Epub 2021 Jul 14. PMID: 34261756.
Copy Download .nbib Format: NLM
Combination treatment optimization using a pan-cancer pathway model.

PLoS computational biology

Schmucker R, Farina G, Faeder J, Fröhlich F, Saglam AS, Sandholm T.
PMID: 34962919
PLoS Comput Biol. 2021 Dec 28;17(12):e1009689. doi: 10.1371/journal.pcbi.1009689. Epub 2021 Dec 28.

The design of efficient combination therapies is a difficult key challenge in the treatment of complex diseases such as cancers. The large heterogeneity of cancers and the large number of available drugs renders exhaustive in vivo or even in...

Cite
Schmucker R, Farina G, Faeder J, et al. Combination treatment optimization using a pan-cancer pathway model. PLoS Comput Biol. 2021;17(12):e1009689doi: 10.1371/journal.pcbi.1009689.
Schmucker, R., Farina, G., Faeder, J., Fröhlich, F., Saglam, A. S., & Sandholm, T. (2021). Combination treatment optimization using a pan-cancer pathway model. PLoS computational biology, 17(12), e1009689. https://doi.org/10.1371/journal.pcbi.1009689
Schmucker, Robin, et al. "Combination treatment optimization using a pan-cancer pathway model." PLoS computational biology vol. 17,12 (2021): e1009689. doi: https://doi.org/10.1371/journal.pcbi.1009689
Schmucker R, Farina G, Faeder J, Fröhlich F, Saglam AS, Sandholm T. Combination treatment optimization using a pan-cancer pathway model. PLoS Comput Biol. 2021 Dec 28;17(12):e1009689. doi: 10.1371/journal.pcbi.1009689. Epub 2021 Dec 28. PMID: 34962919.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 30 entries